Laboratory of Lymphocyte Signaling and Oncoproteome

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL)

Staber, Philipp B.Herling, MarcoBellido, MarJacobsen, Eric D.Davids, Matthew S.Kadia, Tapan MahendraShustov, AndreiTournilhac, OlivierBachy, EmmanuelZaja, FrancescoPorkka, KimmoHoermann, GregorSimonitsch, IngridHaferlach, ClaudiaKubicek, StefanMayerhoefer, MariusHopfinger, GeorgJaeger, UlrichDearden, Claire
Blood July, 2019doi: 10.1182/blood.2019000402ISSN: 1528-0020

T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. With the advent of novel treatment options that will potentially change the management of T-PLL patients it has become necessary to produce consensus guidelines for the design and conduct of clinical trials. The T-PLL International Study group (TPLL-ISG)set out to define standardized criteria for diagnosis, treatment indication, and evaluation of response. These criteria will facilitate comparison of results from clinical trials in T-PLL and will thus support clinical decision making as well as the approval of new therapeutics by healthcare authorities.

Full text


New article accepted for publication

New article accepted for publication

August 30, 2020

Our work on T-PLL cells resembling the phenotype of activated memory-type effector T-cells has been accepted in Blood

Alkylating deacetylase inhibitor tinostamustine in T-PLL

March 11, 2020

New letter evaluating the effects of EDO-S101/tinostamustine published in Leukemia.

Advances and Perspectives in the Treatment of T-PLL

Advances and Perspectives in the Treatment of T-PLL

February 25, 2020

New review on current and future strategies in treating T-PLL published in Current Hematologic Malignancy Reports

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

November 21, 2019

New meta-analysis on JAK/STAT genomic alterations in T-PLL published in Cancers.